BD Reports Strong Q1 FY2025 Results with $5.2 Billion in Revenue, Exceeding Expectations
BD
Medical Device R&D Manufacturer, Distributor
Recently,BD MedicalBecton, Dickinson and Company announced itsFirst Quarter of Fiscal Year 2025The financial report results.Earnings Report Shows BD's Strong Performance in Strategic Transformation and Business Growth, Exceeding Expectations in Revenue, Profit Margin, and Earnings Per Share.
Chairman, CEO and President of BD MedicalTom PolenStated: "We achieved strong operational performance in the first quarter, with revenue growth, margin improvement, and earnings per share all exceeding expectations. WeContinuing transformation through BD 2025 strategy and planning to spin off bioscience and diagnostic solutions businesses"This will further unlock value. Our team has excelled in executing the BD 2025 strategy and driving business innovation, laying a solid foundation for future growth."
Previous article:Spin Off Billion-Dollar Business, Transform into Medical Device Company: Major Moves by Multinational Corporation! Full PPT Attached
# Financial Highlights for the First Quarter
Income: Revenue in the first quarter reached 5.2 billion US dollars (approximately 37.9 billion RMB),An increase of 9.8% year-over-year,Growth was 9.6% at constant exchange rates, with organic growth at 3.9%.
Earnings Per Share: GAAP EPS was $1.04, an increase of 8.3% year-over-year; adjusted EPS was $3.43, an increase of 28.0% year-over-year.
Stock Repurchase: As of the first quarter of fiscal year 2025, BD has completed a $750 million share repurchase program.
Annual Expectation Adjustment: The company raised its adjusted earnings per share guidance for the fiscal year 2025 to $14.30-$14.60, reflecting strong performance in the first quarter and confidence in full-year growth.
# Business Segment Performance
1.Medical Department（BD Medical）：Revenue is$2.615 billion, year-on-year growth17.3%, mainly due to the strong performance of Medication Delivery Solutions and Medication Management Solutions.
2. Life Sciences Division(BD Life Sciences): Revenue is$12.97 billion, year-on-year growth0.7%, mainly due to the steady growth in Specimen Management and Diagnostic Solutions.
3. Intervention Department(BD Interventional): Revenue is$1.257 billion, year-on-year growth5.8%Mainly due to the strong performance of Surgery and Peripheral Intervention businesses.
# Recent Business Highlights
Stock Repurchase Plan: The BD Board of Directors authorized the repurchase of up to 10 million shares of common stock, further enhancing shareholder value.
Innovation and Collaboration: BD has made innovative progress in multiple fields, including accelerating drug discovery and development through collaboration with Biosero, as well as launching an innovative fingertip blood testing technology.
Market Expansion: BD Medical increased the capacity of its U.S. manufacturing network to meet the ongoing demand for critical medical devices such as syringes, needles, and intravenous catheters.
# Annual Outlook
BD Maintains Optimistic Outlook for Full-Year 2025 Performance, Raises Adjusted Earnings Per Share Guidance. The company forecasts full-year revenue to be between $21.7 billion and $21.9 billion, with adjusted earnings per share expected in the range of $14.30 to $14.60, representing year-over-year growth of approximately 8.8% to 11.0%.
